2025/03/27 更新

写真a

イハラ ヤスタカ
井原 康貴
Ihara Yasutaka
所属
附属病院 講師
職名
講師
連絡先
メールアドレス
プロフィール

お問い合わせ:ihara.yasutaka.gr@ehime-u.ac.jp

外部リンク

学位

  • 博士(医学) ( 2024年9月   大阪市立大学大学 )

研究キーワード

  • リアルワールドデータ

  • 医療ビックデータ

  • 薬剤疫学

  • 臨床試験

  • 臨床疫学

  • 疫学

学歴

  • 大阪市立大学   大学院医学系研究科   臨床医科学専攻, 博士課程, 医療統計学

    2021年4月 - 2024年9月

      詳細を見る

    備考: 早期修了

    researchmap

経歴

  • 愛媛大学医学部附属病院   臨床研究支援センター 臨床研究推進部門   講師

    2025年1月 - 現在

      詳細を見る

  • 第一三共株式会社データインテリジェンス部リアルワールドエビデンスグループ

    2024年3月 - 2024年12月

      詳細を見る

  • 大阪公立大学大学院医学系研究科   医療統計学教室   特任研究員

    2022年11月 - 2024年3月

      詳細を見る

  • 大阪公立大学大学院医学系研究科   医療統計学教室   研究補佐

    2021年4月 - 2022年10月

      詳細を見る

所属学協会

  • 日本薬剤疫学会

    2024年4月 - 現在

      詳細を見る

  • 日本癌学会

    2024年2月 - 現在

      詳細を見る

  • 日本薬学会

    2024年1月 - 現在

      詳細を見る

  • 日本医療薬学会

    2023年5月 - 現在

      詳細を見る

委員歴

  • 九州生物統計ネットワーク  

    2025年2月 - 現在   

      詳細を見る

取得資格

  • 薬剤師

論文

  • Real world treatment patterns in patients with eosinophilic esophagitis in Japan 査読

    Akinari Sawada, Yasutaka Ihara, Takumi Imai, Fumio Tanaka, Yasuhiro Fujiwara

    Scientific Reports   14 ( 1 )   2024年11月

     詳細を見る

    担当区分:筆頭著者   掲載種別:研究論文(学術雑誌)   出版者・発行元:Springer Science and Business Media LLC  

    DOI: 10.1038/s41598-024-78868-4

    researchmap

    その他リンク: https://www.nature.com/articles/s41598-024-78868-4

  • Immunotherapy and Overall Survival Among Patients With Advanced Non–Small Cell Lung Cancer and Obesity 査読

    Yasutaka Ihara, Kenji Sawa, Takumi Imai, Tsubasa Bito, Yuki Shimomura, Ryota Kawai, Ayumi Shintani

    JAMA Network Open   7 ( 8 )   e2425363 - e2425363   2024年8月

     詳細を見る

    担当区分:筆頭著者, 責任著者   掲載種別:研究論文(学術雑誌)   出版者・発行元:American Medical Association (AMA)  

    IMPORTANCE

    The association between obesity and response to cancer treatment and survival remains unclear, with conflicting findings from various studies. The optimal choice between conventional chemotherapy and immunotherapy for first-line treatment remains uncertain in patients with obesity who potentially have an inadequate therapeutic response to immunotherapy.

    OBJECTIVE

    To investigate whether body mass index (BMI) modifies the association of immunotherapy or conventional therapy with overall survival in patients with advanced non–small cell lung cancer (aNSCLC).

    DESIGN, SETTING, and PARTICIPANTS

    A retrospective cohort study, using administrative claims data obtained from advanced treatment centers in Japan, was conducted between December 1, 2015, and January 31, 2023. Participants included individuals aged 18 years or older with aNSCLC who received immunotherapy, using immune checkpoint inhibitor (ICI) treatment or conventional chemotherapy.

    EXPOSURE

    Immune checkpoint inhibitor therapy as first-line chemotherapy was compared with conventional chemotherapy, identified through patient medical records.

    MAIN OUTCOMES AND MEASURES

    The main outcome was overall survival. Survival analysis covered a 3-year follow-up period after the first-line chemotherapy.

    RESULTS

    A total of 31 257 patients with aNSCLC were identified. Of these, 12 816 patients received ICI therapy (mean [SD] age, 70.2 [9.1] years; 10 287 [80.3%] men) and 18 441 patients received conventional chemotherapy (mean [SD] age, 70.2 [8.9] years; 14 139 [76.7%] men). Among patients with BMI less than 28, ICI therapy was associated with a significantly lower hazard of mortality (eg, BMI 24: hazard ratio [HR], 0.81; 95% CI, 0.75-0.87) compared with those who underwent conventional chemotherapy. However, no such association was observed among patients with BMI 28 or greater (eg, BMI 28: HR, 0.90; 95% CI, 0.81-1.00).

    CONCLUSIONS AND RELEVANCE

    The findings of this retrospective cohort study suggest that BMI modifies the association of ICI therapy compared with conventional chemotherapy with overall survival in patients with aNSCLC. A lack of association between ICI therapy and improved survival in patients with aNSCLC and overweight or obesity compared with conventional chemotherapy was observed. This suggests that ICI therapy may not be the optimal first-line therapy for patients with overweight or obesity and the use of conventional chemotherapy should also be considered in such patients.

    DOI: 10.1001/jamanetworkopen.2024.25363

    researchmap

  • Incidence and risk factors for coronavirus disease 2019‐associated pulmonary aspergillosis using administrative claims data 査読

    Waki Imoto, Yasutaka Ihara, Takumi Imai, Ryota Kawai, Koichi Yamada, Yukihiro Kaneko, Ayumi Shintani, Hiroshi Kakeya

    Mycoses   67 ( 8 )   2024年8月

     詳細を見る

    担当区分:筆頭著者   掲載種別:研究論文(学術雑誌)   出版者・発行元:Wiley  

    Abstract

    Background

    Coronavirus disease 2019 (COVID‐19)‐associated pulmonary aspergillosis (CAPA) is one of the noticeable complications of COVID‐19 and its incidence varies widely. In Japan, research on the incidence, risk factors and mortality associated with CAPA is limited.

    Objectives

    This study aimed to explore the incidence and potential risk factors for CAPA in patients with severe or critical COVID‐19 and evaluate the relationship between CAPA and mortality of patients with severe or critical COVID‐19.

    Methods

    We investigated the incidence of CAPA in patients with severe and critical COVID‐19 using administrative claims data from acute care hospitals in Japan. We employed multivariable regression models to explore potential risk factors for CAPA and their contribution to mortality in patients with severe and critical COVID‐19.

    Results

    The incidence of CAPA was 0.4%–2.7% in 33,136 patients with severe to critical COVID‐19. Age, male sex, chronic lung disease, steroids, immunosuppressants, intensive care unit admission, blood transfusion and dialysis were potential risk factors for CAPA in patients with severe to critical COVID‐19. CAPA was an independent factor associated with mortality.

    Conclusions

    CAPA is a serious complication in patients with severe and critical COVID‐19 and may increase mortality.

    DOI: 10.1111/myc.13773

    researchmap

  • Pre-cooling for Reducing Pain from Local Anesthetic Injections for Hemorrhoidectomy: An Open-label, Randomized, Crossover Trial 査読

    Takaaki Yano, Yasutaka Ihara, Hisako Yoshida, Takumi Imai, Ryota Kawai, Ayumi Shintani

    Journal of the Anus, Rectum and Colon   8 ( 3 )   221 - 227   2024年7月

     詳細を見る

    担当区分:筆頭著者   掲載種別:研究論文(学術雑誌)   出版者・発行元:The Japan Society of Coloproctology  

    DOI: 10.23922/jarc.2024-002

    researchmap

  • Immune Checkpoint Inhibitor Is Associated with Improved Survival in Advanced Non-small Cell Lung Cancer Occurring in Patients with Autoimmune Disease 査読

    Yasutaka Ihara, Kenji Sawa, Takumi Imai, Yuta Nonomiya, Yuki Shimomura, Asahi Ishihara, Ayumi Shintani

    Biological and Pharmaceutical Bulletin   47 ( 2 )   454 - 461   2024年2月

     詳細を見る

    担当区分:筆頭著者, 責任著者   掲載種別:研究論文(学術雑誌)   出版者・発行元:Pharmaceutical Society of Japan  

    DOI: 10.1248/bpb.b23-00713

    researchmap

  • Renin-angiotensin-aldosterone system inhibitors are associated with improved paclitaxel-induced peripheral neuropathy in lung cancer: a study using administrative claims data. 査読 国際誌

    Yasutaka Ihara, Kenji Sawa, Takumi Imai, Tetsuya Kimura, Miho Otani, Ryota Kawai, Shingo Takatori, Ayumi Shintani

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer   31 ( 12 )   730 - 730   2023年11月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) has been reported to reduce patients' quality of life and impair cancer treatment by causing anticancer drug withdrawal or interruption. However, there are currently no effective methods for the prevention of CIPN. Renin-angiotensin-aldosterone system (RAAS) inhibitors may be associated with a reduced risk of developing oxaliplatin-induced peripheral neuropathy, and it would be valuable to examine whether they have the same effect on CIPN caused by other anticancer drugs. Our study explored the potential preventive effects of RAAS inhibitors on preventing paclitaxel-induced peripheral neuropathy (PIPN). METHODS: An exploratory cohort study was conducted using commercially available administrative claims data on lung cancer patients treated with paclitaxel-based chemotherapy. Cumulative paclitaxel doses, RAAS inhibitor prescriptions, and incidences of PIPN were identified using patient medical records. Fine-Gray analyses with death as a competing risk were performed. A propensity score approach was applied to address the problem of confounding. RESULTS: Patients with lung cancer who received paclitaxel-based chemotherapy were classified into users of RAAS inhibitor (n = 1320) and non-users of RAAS inhibitor (n = 4566). The doses of RAAS inhibitors in our study were similar to those commonly used to treat hypertension. The PIPN incidence was significantly lower in users of RAAS inhibitor than in the non-users of RAAS inhibitor (sub-distribution hazard ratio, 0.842; 95% confidence interval, 0.762-0.929). The result was consistent in various sensitivity analyses and important subgroup analyses. CONCLUSIONS: RAAS inhibitors at doses commonly used for hypertension were associated with a reduced incidence of PIPN in patients with lung cancer.

    DOI: 10.1007/s00520-023-08193-5

    PubMed

    researchmap

  • Incidence and potential risk factors of human cytomegalovirus infection in patients with severe and critical coronavirus disease 2019 査読

    Waki Imoto, Takumi Imai, Ryota Kawai, Yasutaka Ihara, Yuta Nonomiya, Hiroki Namikawa, Koichi Yamada, Hisako Yoshida, Yukihiro Kaneko, Ayumi Shintani, Hiroshi Kakeya

    Journal of Infection and Chemotherapy   31 ( 1 )   102452 - 102452   2025年1月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Elsevier BV  

    DOI: 10.1016/j.jiac.2024.06.015

    PubMed

    researchmap

  • Epidemiology and risk factors of non-esophageal eosinophilic gastrointestinal diseases in Japan: A population-based study 査読

    Akinari Sawada, Takumi Imai, Yasutaka Ihara, Fumio Tanaka, Yasuhiro Fujiwara

    Allergology International   2024年12月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Elsevier BV  

    DOI: 10.1016/j.alit.2024.10.007

    researchmap

  • Immunotherapy Following Anaplastic Lymphoma Kinase Inhibitor Therapy for Patients with Anaplastic Lymphoma Kinase‑Positive Non‑small Cell Lung Cancer in Japan 査読

    Yuki Shimomura, Megumi Mizutani, Hisako Yoshida, Yasutaka Ihara, Ayumi Shintani

    Targeted Oncology   2024年11月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Springer Science and Business Media LLC  

    DOI: 10.1007/s11523-024-01116-2

    PubMed

    researchmap

    その他リンク: https://link.springer.com/article/10.1007/s11523-024-01116-2/fulltext.html

  • Evaluating the association of body mass index with COVID-19 severity and mortality using Japanese administrative claims data 査読

    Waki Imoto, Yasutaka Ihara, Takumi Imai, Mitsuhiro Tamoto, Tatoi Ibuki, Koichi Yamada, Yukihiro Kaneko, Ayumi Shintani, Hiroshi Kakeya

    Journal of Infection and Chemotherapy   30 ( 10 )   1054 - 1060   2024年10月

     詳細を見る

    担当区分:筆頭著者   掲載種別:研究論文(学術雑誌)   出版者・発行元:Elsevier BV  

    DOI: 10.1016/j.jiac.2024.04.007

    researchmap

  • Epidemiology and Risk Factors of Eosinophilic Esophagitis in Japan: A Population-Based Study 査読

    Akinari Sawada, Takumi Imai, Yasutaka Ihara, Fumio Tanaka, Ikuo Hirano, Yasuhiro Fujiwara

    Clinical Gastroenterology and Hepatology   22 ( 10 )   2023 - 2032.e6   2024年10月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Elsevier BV  

    DOI: 10.1016/j.cgh.2024.04.035

    researchmap

  • Association Between Febuxostat Use and the Incidence of Cardiovascular Events, Mortality, and Kidney Events in Patients With Chronic Kidney Disease Compared to Allopurinol: A Study Using a Japanese Nationwide Database. 査読 国際誌

    Miho Otani, Yuta Nonomiya, Yasutaka Ihara, Ryota Kawai, Satsuki Taniuchi, Hisako Yoshida, Kazuhiko Tsuruya, Ayumi Shintani

    Cureus   16 ( 9 )   e70351   2024年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Background Patients with chronic kidney disease (CKD) were excluded in most trials that investigated the effects of urate-lowering agents, such as febuxostat and allopurinol, in hyperuricemic patients. This exclusion leads to uncertainty regarding the efficacy of febuxostat in patients with CKD. Due to the high prevalence of hyperuricemia in patients with CKD, we aimed to assess the effect of febuxostat on improving patient outcomes concerning cardiovascular events and survival compared with those treated with allopurinol among patients with CKD. Methods We conducted a retrospective cohort study using Japanese nationwide administrative data from Jan 1, 2013, to Sep 30, 2020. Patients aged over 60 years diagnosed with CKD were included in this study if they were prescribed either febuxostat or allopurinol. The primary outcome was the occurrence of cardiovascular events including myocardial infarction, stroke, unstable angina requiring urgent revascularization, and all-cause deaths. We estimated hazard ratios (HR) and 95% CI using a Cox proportional hazard regression model adjusted for comorbidities, medications, and laboratory data. We also assessed defined starting kidney replacement therapy as a secondary endpoint treating death as a competing risk using the Fine & Gray regression model. Results A total of 21,015 patients included those with febuxostat (n=17,796) and those with allopurinol (n=3,219). The association between the type of drug and the occurrence of cardiovascular events did not show a significant difference (0.107 vs. 0.116 events per patient-year; adjusted HR 0.953, 95% CI: 0.854 to 1.062, P=0.381). Similar results were seen for all-cause deaths (0.060 vs. 0.068 events per patient-year; adjusted HR 0.877, 95% CI: 0.760 to 1.012, P=0.073). Regarding the secondary endpoint, the association between the type of drug and the timing of starting kidney replacement therapy did not show a significant difference (0.118 vs. 0.097 events per patient-year; adjusted HR 0.953, 95% CI: 0.854 to 1.062, P=0.425). Conclusion The use of febuxostat was neither associated with a decreased risk of cardiovascular events or deaths nor with the timing of starting kidney replacement therapy compared to the use of allopurinol in patients with CKD.

    DOI: 10.7759/cureus.70351

    PubMed

    researchmap

  • Lack of Association Between Immunotherapy and Improvement of Survival for Non-small Cell Lung Cancer Patients With Hemodialysis: A Nationwide Retrospective Cohort Study 査読

    Kenji Sawa, Yasutaka Ihara, Takumi Imai, Akira Sugimoto, Hiroaki Nagamine, Koichi Ogawa, Kenji Nakahama, Yoshiya Matsumoto, Yoko Tani, Hiroyasu Kaneda, Shigeki Mitsuoka, Tomoya Kawaguchi, Ayumi Shintani

    Clinical Lung Cancer   25 ( 2 )   144 - 150.e3   2024年3月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Elsevier BV  

    DOI: 10.1016/j.cllc.2023.11.003

    PubMed

    researchmap

  • Seasonal variations for newly prescribed urate-lowering drugs for asymptomatic hyperuricemia and gout in Japan 査読

    Masafumi Kurajoh, Seigo Akari, Takashi Nakamura, Yasutaka Ihara, Takumi Imai, Tomoaki Morioka, Masanori Emoto

    Frontiers in Pharmacology   15   2024年1月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Frontiers Media SA  

    Background: Urate-lowering drugs (ULDs) have been approved for treatment of asymptomatic hyperuricemia and gout in Japan. Although serum urate levels and rates of gout onset are known to have seasonal variations, no survey results regarding the seasonality of ULD prescriptions for asymptomatic hyperuricemia and gout have been reported.

    Methods: A large-scale database of medical claims in Japan filed between January 2019 and December 2022 was accessed. In addition to total size of the recorded population for each month examined, the numbers of patients every month with newly prescribed ULDs for asymptomatic hyperuricemia and gout were noted, based on the International Classification of Diseases, 10th Revision, codes E79.0 and M10.

    Results: The results identified 201,008 patients with newly prescribed ULDs (median age 49.0 years, male 95.6%). Of those, 64.0% were prescribed ULDs for asymptomatic hyperuricemia and 36.0% for gout. The proportion of new ULD prescriptions was seasonal, with that significantly (p < 0.001) higher in summer (June–August) [risk ratio (RR) 1.322, 95% CI 1.218 to 1.436] and autumn (September–November) (RR 1.227, 95% CI 1.129–1.335) than in winter (December–February), whereas the proportion in spring (March–May) was not significantly different from winter. There was no significant difference after stratification by drug type (uric acid production inhibitor/uricosuric agent) or size of the medical institution, nor subgrouping by age or sex (p for interaction = 0.739, 0.727, 0.886, and 0.978, respectively). On the other hand, the proportions of new ULD prescriptions for asymptomatic hyperuricemia were significantly lower and for gout significantly higher in spring than winter, while those were similar in summer and autumn for both groups (p for interaction<0.001).

    Conclusion: The present findings indicate that new prescriptions for ULDs to treat asymptomatic hyperuricemia or gout in Japan show seasonal differences, with higher rates noted in summer and autumn as compared to winter.

    DOI: 10.3389/fphar.2024.1230562

    researchmap

  • Treatment sequencing after failure to alectinib in patients with anaplastic lymphoma kinase‐positive non‐small‐cell lung cancer 査読

    Yuki Shimomura, Kenji Sawa, Takumi Imai, Yasutaka Ihara, Hisako Yoshida, Ayumi Shintani

    Cancer Science   115 ( 3 )   926 - 936   2023年12月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Wiley  

    Abstract

    Alectinib is the first‐line therapy for anaplastic lymphoma kinase‐positive non‐small‐cell lung cancer. Although some guidelines have recommended using other anaplastic lymphoma kinase inhibitors after alectinib failure, evidence for such regimens in patients who fail to respond to alectinib is limited. This study involved using administrative claims data from acute care hospitals in Japan. We extracted the data of 634 patients diagnosed with lung cancer between September 1, 2014, and January 31, 2023, who received alectinib treatment before treatment with another anaplastic lymphoma kinase inhibitor. We assessed distributions of patients according to their treatment sequencing and prognosis among three periods defined based on the initial marketing dates of lorlatinib and brigatinib. The type of anaplastic lymphoma kinase inhibitors after alectinib failure changed over time. In the most recent period, lorlatinib (58%) and brigatinib (40%) became predominant. Two‐year overall survival improved over time (47%–84%), accompanied by an increased 2‐year proportion of patients who continuously used anaplastic lymphoma kinase inhibitors after alectinib failure (13%–44%). The times to treatment discontinuation of the regimen between patients treated with lorlatinib and brigatinib were similar, with a hazard ratio of 1.02 (95% confidence interval, 0.64–1.64) in the period after marketing brigatinib. This study provides insights into the evolving treatment landscape for patients with anaplastic lymphoma kinase‐positive non‐small‐cell lung cancer who experience failed alectinib treatment and highlights the need for further studies and data accumulation to determine the optimal treatment strategy.

    DOI: 10.1111/cas.16056

    PubMed

    researchmap

  • Association of plasma xanthine oxidoreductase activity with vascular endothelial function independent of serum uric acid level: MedCity21 health examination registry. 査読 国際誌

    Masafumi Kurajoh, Shinya Fukumoto, Seigo Akari, Takayo Murase, Takashi Nakamura, Yasutaka Ihara, Takumi Imai, Yuki Nagata, Tomoaki Morioka, Katsuhito Mori, Yasuo Imanishi, Toshio Watanabe, Masanori Emoto

    International journal of cardiology. Heart & vasculature   48   101264 - 101264   2023年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Xanthine oxidoreductase (XOR) inhibitor administration, known to reduce uric acid and reactive oxygen species (ROS) production, also improves vascular endothelial function (VEF). This cross-sectional study examined our hypothesis that XOR contributes to impaired VEF through ROS but not uric acid production. METHODS: In 395 subjects (196 males, 199 females) without urate-lowering agent administration who underwent a health examination, plasma XOR activity was determined using our highly sensitive assay based on [13C2,15N2] xanthine and liquid chromatography/triple quadrupole mass spectrometry. For VEF evaluation, flow-mediated dilatation (FMD) in the brachial artery was determined by ultrasound, with physical and laboratory measurements also obtained. RESULTS: The median values for plasma XOR activity, serum uric acid, and FMD were 26.6 pmol/h/mL, 5.4 mg/dL, and 6.2%, respectively. Simple regression analysis showed weak correlations of both log plasma XOR activity and serum uric acid level with FMD (r = -0.213, p < 0.001 and r = -0.139, p = 0.006, respectively). However, multivariable linear regression analyses revealed that log plasma XOR activity but not serum uric acid level remained associated with FMD (β = -0.116, p = 0.037 and β = 0.041, p = 0.549, respectively) after adjustments for various clinical parameters, with no remarkable inconsistencies for the association observed in subgroups divided based on sex or uric acid level. Finally, a series of mediation analyses showed that serum uric acid level did not meet the criteria for mediator of the association of plasma XOR activity with FMD (p = 0.538). CONCLUSIONS: These findings suggest the possibility that XOR contributes to the pathophysiology of impaired VEF through ROS but not uric acid production.

    DOI: 10.1016/j.ijcha.2023.101264

    PubMed

    researchmap

  • Inflammation Related to Association of Low Uric Acid and Progression to Severe Disease in Patients Hospitalized for Non-Severe Coronavirus Disease 2019. 査読 国際誌

    Masafumi Kurajoh, Yoshikazu Hiura, Ryutaro Numaguchi, Yasutaka Ihara, Takumi Imai, Tomoaki Morioka, Masanori Emoto, Yukio Nishiguchi

    Biomedicines   11 ( 3 )   2023年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Uric acid has antioxidant properties. To examine whether a low uric acid level is associated with severe coronavirus disease 2019 (COVID-19) progression via inflammation, alveolar damage, and/or coagulation abnormality, a retrospective observational study of 488 patients with non-severe COVID-19 and serum uric acid level ≤7 mg/dL at admission was conducted. Serum C-reactive protein (CRP), serum Krebs von den Lungen 6 (KL-6), and plasma D-dimer levels were also measured as markers of inflammation, alveolar damage, and coagulation abnormality, respectively. Median values for uric acid, CRP, KL-6, and D-dimer at admission were 4.4 mg/dL, 3.33 mg/dL, 252.0 U/mL, and 0.8 µg/mL, respectively. Among the total cohort, 95 (19.5%) progressed to severe COVID-19 with a median (interquartile range) time of 7 (4-14) days. Multivariable Cox proportional hazards regression analysis showed that low uric acid level was associated with a higher rate of severe COVID-19 progression. However, uric acid level was inversely associated with CRP level, and the association between the level of uric acid and severe COVID-19 progression was significantly different with and without CRP level inclusion. In contrast, no such association was found for KL-6 or D-dimer level. Low uric acid may contribute to severe COVID-19 progression via increased inflammation in subjects without hyperuricemia.

    DOI: 10.3390/biomedicines11030854

    PubMed

    researchmap

  • Reduced Risk of Progression from Non-Severe to Severe COVID-19 in Hospitalized Dialysis Patients by Full COVID-19 Vaccination. 査読 国際誌

    Mitsuru Ichii, Masafumi Kurajoh, Yujiro Okute, Yasutaka Ihara, Takumi Imai, Tomoaki Morioka, Katsuhito Mori, Tetsuo Shoji, Yoshihiro Tsujimoto, Takanobu Ubai, Masanori Emoto

    Journal of clinical medicine   11 ( 21 )   2022年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Coronavirus disease 2019 (COVID-19) vaccination reduces the risk of progression to severe COVID-19 in the general population. To examine that preventive effect in dialysis patients, the association of vaccination status with severe COVID-19 progression was investigated in this retrospective observational study conducted from December 2020 to May 2022 of 100 such patients hospitalized for non-severe COVID-19 at Inoue Hospital (Suita, Japan). Fifty-seven were fully vaccinated, defined as receiving a COVID-19 vaccine second dose at least 14 days prior to the onset of COVID-19, while 43 were not. Among all patients, 13 (13.0%) progressed to severe COVID-19 with a median (interquartile range) time of 6 (2.5-9.5) days, while 87 (87.0%) were discharged after 11 (8-16) days. Kaplan-Meier analysis showed that fully vaccinated patients had a significantly lower rate of progression to severe COVID-19 (p = 0.001, log-rank test). Cox proportional hazard analysis also indicated that full COVID-19 vaccination was significantly associated with reduced instances of progression to severe COVID-19 (hazard ratio 0.104, 95% confidence interval 0.022 to 0.483; p = 0.004) after balancing patient background characteristics using an inverse probability of treatment weight method. These results suggest that full vaccination status contributes to reducing the risk of progression from non-severe to severe COVID-19 in dialysis patients.

    DOI: 10.3390/jcm11216348

    PubMed

    researchmap

▼全件表示

MISC

  • Sa1277 INCIDENCE AND RISK FACTORS OF NONESOPHAGEAL EOSINOPHILIC GASTROINTESTINAL DISORDERS IN JAPAN: A POPULATION-BASED STUDY

    Akinari Sawada, Takumi Imai, Yasutaka Ihara, Fumio Tanaka, Yasuhiro Fujiwara

    Gastroenterology   166 ( 5 )   S - 413   2024年5月

     詳細を見る

    出版者・発行元:Elsevier BV  

    DOI: 10.1016/s0016-5085(24)01429-x

    researchmap

  • Sa1276 INCIDENCE AND RISK FACTORS OF EOSINOPHILIC ESOPHAGITIS IN JAPAN: A POPULATION-BASED STUDY

    Akinari Sawada, Takumi Imai, Yasutaka Ihara, Fumio Tanaka, Yasuhiro Fujiwara

    Gastroenterology   166 ( 5 )   S - 413   2024年5月

     詳細を見る

    出版者・発行元:Elsevier BV  

    DOI: 10.1016/s0016-5085(24)01428-8

    researchmap

  • 本邦における無症候性高尿酸血症・痛風に対する尿酸降下薬新規処方の季節性の検討

    藏城雅文, 赤利精悟, 中村敬志, 井原康貴, 今井匠, 森岡与明, 繪本正憲

    日本内分泌学会雑誌   100 ( 1 )   2024年

     詳細を見る

  • Febuxostat vs. Allopurinol in CKD Patients: Observational Study on Cardiovascular Events and Deaths

    Miho Otani, Sae Shinomiya, Yasutaka Ihara, Ryota Kawai, Hisako Yoshida, Kazuhiko Tsuruya, Ayumi Shintani

    Journal of the American Society of Nephrology   34 ( 11S )   353 - 353   2023年11月

     詳細を見る

    出版者・発行元:Ovid Technologies (Wolters Kluwer Health)  

    DOI: 10.1681/asn.20233411s1353b

    researchmap

  • 血漿中キサンチン酸化還元酵素活性は血清尿酸値と独立して血管内皮機能と関連する

    藏城雅文, 福本真也, 赤利精悟, 村瀬貴代, 中村敬志, 井原康貴, 今井匠, 永田友貴, 森岡与明, 森克仁, 今西康雄, 繪本正憲

    日本内分泌学会雑誌   99 ( 1 )   2023年

     詳細を見る

  • レニン・アンジオテンシン系阻害剤とパクリタキセル誘発性末梢神経障害の関連:DPCデータを用いたレトロスペクティブ観察研究

    井原康貴, 今井匠, 木村哲也, 木村哲也, 河合稜太, 高取真吾, 新谷歩

    Pain Research   37 ( 4 )   2022年

     詳細を見る

▼全件表示

講演・口頭発表等

  • The advantage of robotic gastrectomy over laparoscopic gastrectomy:a propensity score match analysis using administrative claims data

    Yuichiro Miki, Tsubasa Bito, Ryota Kawai, Mami Yoshii, Yasutaka Ihara, Kenji Kuroda, Kiyoshi Maeda, Ayumi Shintani

    Korea International Gastric Cancer Week 2024  2024年9月 

     詳細を見る

    開催年月日: 2024年9月

    researchmap

  • 本邦における無症候性高尿酸血症・痛風に対する尿酸降下薬新規処方の季節性の検討

    藏城雅文, 赤利精悟, 中村敬志, 井原康貴, 今井匠, 森岡与明, 繪本正憲

    日本内分泌学会雑誌  2024年6月 

     詳細を見る

    開催年月日: 2024年6月

    researchmap

  • INCIDENCE AND RISK FACTORS OF NONESOPHAGEAL EOSINOPHILIC GASTROINTESTINAL DISORDERS IN JAPAN: A POPULATION-BASED STUDY

    Akinari Sawada, Takumi Imai, Yasutaka Ihara, Fumio Tanaka, Yasuhiro Fujiwara

    Gastroenterology  2024年5月 

     詳細を見る

    開催年月日: 2024年5月

    researchmap

  • 肥満のある進行非小細胞肺癌患者に対する初回免疫療法と生存率改善との関連は認められない

    井原 康貴, 澤 兼士, 今井 匠, 下村 由希, 河合 稜太, 新谷 歩

    日本薬学会第144年会  2024年3月 

     詳細を見る

    開催年月日: 2024年3月

    researchmap

  • Febuxostat vs. Allopurinol in CKD Patients: Observational Study on Cardiovascular Events and Deaths

    Miho Otani, Sae Shinomiya, Yasutaka Ihara, Ryota Kawai, Hisako Yoshida, Kazuhiko Tsuruya, Ayumi Shintani

    American Society of Nephrology Kidney Week 2023  2023年11月 

     詳細を見る

    開催年月日: 2023年11月

    researchmap

  • 自己免疫疾患を有する遠隔転移性非小細胞肺癌患者における免疫チェックポイント阻害剤と全生存率の関連性

    井原 康貴, 澤 兼士, 今井 匠, 石原 朝陽, 下村 由希, 野々宮 悠太, 新谷 歩

    日本医療薬学会  2023年11月 

     詳細を見る

    開催年月日: 2023年11月

    researchmap

  • 血漿中キサンチン酸化還元酵素活性は血清尿酸値と独立して血管内皮機能と関連する

    藏城 雅文, 福本 真也, 赤利 精悟, 村瀬 貴代, 中村 敬志, 井原 康貴, 今井 匠, 永田 友貴, 森岡 与明, 森 克仁, 今西 康雄, 繪本 正憲

    日本内分泌学会雑誌  2023年6月  (一社)日本内分泌学会

     詳細を見る

    開催年月日: 2023年6月

    記述言語:日本語  

    researchmap

  • 血清尿酸値と独立した血漿中キサンチン酸化還元酵素活性と血管内皮機能との関連

    藏城 雅文, 赤利 精悟, 村瀬 貴代, 中村 敬志, 福本 真也, 井原 康貴, 今井 匠, 森岡 与明, 繪本 正憲

    日本痛風・尿酸核酸学会総会プログラム・抄録集  2023年2月  (一社)日本痛風・尿酸核酸学会

     詳細を見る

    開催年月日: 2023年2月

    記述言語:日本語  

    researchmap

  • レニン・アンジオテンシン系阻害剤とパクリタキセル誘発性末梢神経障害の関連 DPCデータを用いたレトロスペクティブ観察研究

    井原 康貴, 今井 匠, 木村 哲也, 河合 稜太, 高取 真吾, 新谷 歩

    PAIN RESEARCH  2022年12月  (一社)日本疼痛学会

     詳細を見る

    開催年月日: 2022年12月

    記述言語:日本語  

    researchmap

  • レニン・アンジオテンシン系阻害剤と化学療法誘発性末梢神経障害の関連:DPCデータを用いた観察研究

    井原 康貴, 今井 匠, 木村 哲也, 河合 稜太, 高取 真吾, 新谷 歩

    第17回 Biostatistics Network  2022年9月 

     詳細を見る

    開催年月日: 2022年9月

    researchmap

  • INCIDENCE AND RISK FACTORS OF EOSINOPHILIC ESOPHAGITIS IN JAPAN: A POPULATION-BASED STUDY

    Akinari Sawada, Takumi Imai, Yasutaka Ihara, Fumio Tanaka, Yasuhiro Fujiwara

    Gastroenterology  2024年5月 

     詳細を見る

▼全件表示

受賞

  • 医学部長賞(奨励賞)

    2025年   大阪公立大学大学院医学系研究科  

     詳細を見る

メディア報道

学術貢献活動

  • JAMA Network Open

    役割:査読

     詳細を見る